Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Assets (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Assets for 13 consecutive years, with $258.3 million as the latest value for Q4 2025.

  • Quarterly Assets fell 42.4% to $258.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $258.3 million through Dec 2025, down 42.4% year-over-year, with the annual reading at $258.3 million for FY2025, 42.4% down from the prior year.
  • Assets hit $258.3 million in Q4 2025 for Coherus Oncology, down from $516.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $763.5 million in Q1 2024 to a low of $258.3 million in Q4 2025.
  • Historically, Assets has averaged $554.4 million across 5 years, with a median of $548.5 million in 2022.
  • Biggest five-year swings in Assets: skyrocketed 89.74% in 2024 and later tumbled 51.4% in 2025.
  • Year by year, Assets stood at $679.3 million in 2021, then decreased by 29.22% to $480.8 million in 2022, then soared by 30.94% to $629.6 million in 2023, then fell by 28.76% to $448.5 million in 2024, then tumbled by 42.4% to $258.3 million in 2025.
  • Business Quant data shows Assets for CHRS at $258.3 million in Q4 2025, $516.5 million in Q3 2025, and $439.5 million in Q2 2025.